Consequences of NMO-IgG binding to aquaporin-4 in neuromyelitis optica.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. From Homeostasis to Pathology: Decoding the Multifaceted Impact of Aquaporins in the Central Nervous System.International journal of molecular sciences · 2023
   Review
2. Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders.Proceedings of the National Academy of Sciences of the United States of America · 2022
   Article
3. Autopsy Case of Meningoencephalomyelitis Associated With Glial Fibrillary Acidic Protein Antibody.Neurology(R) neuroimmunology & neuroinflammation · 2021
   Article
4. Plant and Mammal Aquaporins: Same but Different.International journal of molecular sciences · 2018
   Review
5. Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica.Journal of cellular and molecular medicine · 2018
   Article
6. AQP4e-Based Orthogonal Arrays Regulate Rapid Cell Volume Changes in Astrocytes.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017
   Article
7. Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2017
   Review
8. Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Clinical and experimental immunology · 2014
   Review
9. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.Brain pathology (Zurich, Switzerland) · 2014
   Review
10. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly.Glia · 2012
    Article
11. Molecular pathogenesis of neuromyelitis optica.International journal of molecular sciences · 2012
    Review
12. Super-resolution imaging of aquaporin-4 orthogonal arrays of particles in cell membranes.Journal of cell science · 2012
    Article
13. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.The international journal of biochemistry & cell biology · 2012
    Review
14. Aquaporin 4 and neuromyelitis optica.The Lancet. Neurology · 2012
    Review

Corrections and comments

• Comment on
  Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes.2012

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as